Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rivoceranib + paclitaxel
- Development stage
- Phase 2
- Lead developer
- Elevar Therapeutics
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Rivoceranib + paclitaxel is a combination therapy consisting of rivoceranib, an oral small-molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR-2), and paclitaxel, a microtubule-stabilizing chemotherapeutic agent. Rivoceranib blocks VEGFR-2-mediated signaling pathways, thereby inhibiting tumor angiogenesis and growth. Paclitaxel disrupts microtubule dynamics, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells. This combination has been investigated primarily for the treatment of advanced gastric or gastroesophageal junction (GEJ) cancer as second-line therapy, as well as in gastrointestinal stromal tumors (GIST) with high P-glycoprotein expression after failure of standard therapies. Clinical studies have shown manageable safety profiles and promising efficacy signals for this regimen[1][5].
- Brand names
- Abraxane
- Other names
- Rivoceranib Mesylate + PaclitaxelApatinib + Paclitaxel
02
Targets
MicrotubuleVEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on rivoceranib + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rivoceranib + paclitaxel.